Johnson & Johnson (NYSE:JNJ) Stock Jumps 2.2% – Still a Buy?

Shares of Johnson & Johnson (NYSE:JNJ) were up 2.2% during mid-day trading on Tuesday. The company traded as high as $260.77 and last traded at $259.4190. Approximately 7,633,228 shares changed hands during mid-day trading, a decline of 5% from the average session volume of 7,994,566 shares. The stock had previously closed at $253.79.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson launched the next-generation Shockwave C2 Aero Fly coronary intravascular lithotripsy catheter in the U.S. The device delivers pulses at 2 Hz and is designed to cut treatment time for calcified coronary lesions roughly in half, potentially improving hospital efficiency and supporting MedTech growth. Johnson & Johnson Launches Next-Generation Shockwave C2 Aero Fly Coronary IVL Catheter
• Positive Sentiment: New Phase 3 FUZION data showed TREMFYA maintained or improved fistula remission through 48 weeks in Crohn’s disease, including remission rising to 35% from 28% at Week 24 for one dosing group. The results strengthen the case for expanding TREMFYA’s commercial opportunity beyond its established indications. Johnson & Johnson TREMFYA Crohn’s Disease Data
• Positive Sentiment: TD Cowen reiterated a Buy rating and kept its $300 price target, citing underappreciated pharmaceutical and MedTech growth prospects. TD Cowen Reiterates Buy Rating
• Neutral Sentiment: Johnson & Johnson’s quarterly EPS and revenue edged above consensus, while fiscal 2026 EPS guidance was set at $11.05-$11.15. However, the limited magnitude of the beat indicates that stronger execution may be needed to sustain the stock’s premium earnings multiple.
• Negative Sentiment: JLPascual downgraded JNJ to Sell, adding pressure to a valuation debate: the stock trades at a substantial earnings premium to the broader market, while competition and development spending could limit the returns from its medical-device acquisitions. Johnson & Johnson Downgraded to Sell

Analyst Upgrades and Downgrades

JNJ has been the subject of a number of research reports. Wells Fargo & Company upped their price objective on Johnson & Johnson from $275.00 to $287.00 and gave the company an “overweight” rating in a research report on Friday. Morgan Stanley cut their price target on Johnson & Johnson from $294.00 to $292.00 and set an “overweight” rating for the company in a research note on Thursday, October 15th. JPMorgan Chase & Co. upped their price target on shares of Johnson & Johnson from $270.00 to $285.00 and gave the company a “neutral” rating in a research report on Tuesday, September 29th. Bank of America reiterated a “neutral” rating and issued a $278.00 price objective on shares of Johnson & Johnson in a research note on Tuesday, September 29th. Finally, Weiss Ratings raised shares of Johnson & Johnson from a “buy (b)” rating to a “buy (b+)” rating in a report on Thursday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $275.92.

Johnson & Johnson Trading Up 2.2%

The company has a market capitalization of $625.17 billion, a P/E ratio of 39.31, a PEG ratio of 2.53 and a beta of 0.21. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09. The stock has a fifty day moving average of $265.52 and a 200 day moving average of $249.73.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a return on equity of 31.54% and a net margin of 16.20%. The business had revenue of $25.40 billion during the quarter, compared to analyst estimates of $25.38 billion. During the same quarter in the previous year, the company posted $2.80 earnings per share. Johnson & Johnson’s revenue for the quarter was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, equities research analysts anticipate that Johnson & Johnson will post 11.12 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be issued a $1.34 dividend. This represents a $5.36 annualized dividend and a yield of 2.1%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio is currently 81.21%.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Timothy Schmid sold 33,597 shares of Johnson & Johnson stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the transaction, the executive vice president owned 25,447 shares of the company’s stock, valued at $6,991,308.78. The trade was a 56.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Elizabeth Forminard sold 15,918 shares of the company’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the completion of the transaction, the executive vice president owned 16,994 shares of the company’s stock, valued at approximately $4,367,458. The trade was a 48.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 64,515 shares of company stock worth $17,271,766. Company insiders own 0.16% of the company’s stock.

Institutional Investors Weigh In On Johnson & Johnson

A number of institutional investors have recently bought and sold shares of the business. Jupiter Topco LLC purchased a new stake in Johnson & Johnson during the second quarter worth $1,967,399,000. Diamant Asset Management Inc. increased its holdings in shares of Johnson & Johnson by 24,436.5% in the 1st quarter. Diamant Asset Management Inc. now owns 4,473,008 shares of the company’s stock valued at $109,338,000 after acquiring an additional 4,454,778 shares during the period. Corient Private Wealth LP increased its holdings in shares of Johnson & Johnson by 127.3% in the 2nd quarter. Corient Private Wealth LP now owns 6,060,922 shares of the company’s stock valued at $1,539,292,000 after acquiring an additional 3,393,981 shares during the period. Wellington Management Group LLP raised its position in shares of Johnson & Johnson by 12.5% in the 2nd quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company’s stock worth $5,736,851,000 after acquiring an additional 2,513,321 shares in the last quarter. Finally, Amundi raised its position in shares of Johnson & Johnson by 17.5% in the 1st quarter. Amundi now owns 13,406,820 shares of the company’s stock worth $3,277,163,000 after acquiring an additional 2,001,139 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.